C-Arms Market

Global C-Arms Market Size

As per our report, the size of the global C-arms market was worth USD 3.71 billion in 2024 and is estimated to grow at a CAGR of 3.86% and will reach USD 5.02 billion by 2033. The C-arms market size was valued at USD 3.57 billion in 2024

C-arms are advanced imaging devices that work on the X-ray technology principle. These were invented in 1955, and since then, the industry of C-arms has been significantly evolving. These devices are extensively used in areas such as surgery, orthopedics, traumatology, vascular surgery, and cardiology during routine procedures. C-arms have now become a necessary technology to have in almost all well-equipped hospitals. The latest research and innovations in the field of C-Arms are helping the market grow during the forecast period. The newer technologies and conveniences are promoting their popularity, encouraging market expansion. C-Arms have both fluoroscopic and radiological capabilities helping the segments rise in the market. 

MARKET DRIVERS

Y-O-Y growth in the incidence of chronic diseases worldwide, coupled with the rising geriatric population, drives significant growth in the global C-arms market.

The global market for C-arms is projected to experience exponential growth during the forecast period. Rising chronic diseases around the globe are a significant factor in driving the global C-arms market growth. According to the World Health Organization (WHO), chronic diseases are increasing at a significant pace globally, which is estimated to favor the C-arms market to grow next level. The growing aging population across the globe is another major factor fuelling the market's growth. According to the United Nations, the older population is projected to reach 2.1 billion by 2050. The increase in the aging population is expected to reflect market growth. Areas such as pain management, arthrography, and cardiac catheterization are also widely using C-arms in their medical procedures, which is expected to raise the market demand. In addition, the key manufacturers of C-arms concentrate on R&D activities to bring better treatment quality changes and diagnostic procedures, which are further estimated to accelerate the global C-Arms market growth.

The custom-based utilities and AI systems of C-Arms are expected to help market growth.

The market is supported by technological innovations in the field of C-Arms as it makes it much easier to provide efficient and personalized care to every patient with the use of custom imaging solutions for a wide range of healthcare applications. The C-Arms systems are not only precise and have accurate and quick readings, but they are also now being developed using AI systems for easy access and usage systems leading to development in the healthcare IT segment and supporting market expansion. Furthermore, in recent times of modernization and cloud-based systems, AI is an essential convenience. Therefore, its inclusion in the healthcare sector can help save time and effort, creating immediate treatment possibilities. Therefore, the market is growing due to its continuous efforts to adapt to current situations. 

Furthermore, the shifting trend towards minimally invasive surgical procedures growing prevalence of quality treatment procedures at any cost, is also escalating the C-arms market growth. In addition, increasing demand for high-resolution X-ray images to properly view real-time is another factor accelerating the market. Besides, these devices are highly effective in efficiently performing complicated operations, allowing patients a speedy recovery and elevating the market's growth.

MARKET RESTRAINTS

High costs to curb market growth. However, the cost of installing and maintaining the devices requires massive amounts. Not only the equipment itself but also the installation and the regulation and the maintenance are also costly. Furthermore, the facilities do not have a standard. They are required differently by different people, and the reimbursement policies for the equipment and setups are not very favorable. Therefore the extensive costs of the service and product make it unaffordable in many situations, leading to market drawbacks. 

Additionally, the lack of skilled physicians to monitor the systems and perform work relatively slowly is hampering the growth of the C-arms market. In addition, the rise in risk factors for emergency cases due to a lack of time remains challenging for the market to grow.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Device Type Insights

Based on the type, Mobile C-arms held the highest shares of the market in recent years and continued the same growth rate in the foreseeable years. Increasing awareness over the utilization of devices effectively with the rise in the training institutes is escalating the market's growth to an extent. In addition, introducing specially designed devices that are highly convenient for performing complex tasks is leveling up the market demand. Also, growing research and development to improve the quality of treatment and diagnosis procedures elevate the market's growth in this segment.

However, the fixed C-arms segment is also expected to show significant growth during the forecast period due to its diagnostic and therapeutic applications and reliability as a stable C-Arms system. In addition, it is the most old-school method of C-arms and is used by habituated professionals in their work. 

By Application Insights

Based on the application, the cardiology application type holds dominant market shares. The rise in cardiovascular problems and the increasing success rate of open-heart surgeries are prompting market demand. Also, the rise in healthcare expenditure, especially in urban areas, is likely to outshine the growth of the C-arms market. In addition, the rising chronic heart conditions requiring surgical procedures are helping the segment's expansion. 

Additionally, the Orthopaedic segment is also expected to show fast growth similar to that of the cardiovascular segment due to the rising cases of bone diseases like arthritis in the growing geriatric populations and the increasing need for surgical procedures like knee replacements. Furthermore, the increasing incidence of fractures in accidents supports the segment's growth.

REGIONAL ANALYSIS

Regionally, the North American region holds the highest shares of the global C-arms market owing to the quick adoption of advanced technology. In addition, the introduction of various medical products in the medical sector is also leveraging the market's growth. Furthermore, the region has advanced healthcare infrastructure, rising disposable incomes, and a rapidly urbanizing society supporting the market's growth. Additionally, several key market competitors in countries like the U.S. and Canada are helping the region progress.

Europe is following North America in holding dominant shares of the market. Growing investments in healthcare centers by the government are focused on expanding the market share in this region. Europe is also growing due to the rising geriatric populations and the incidences of surgeries and chronic health conditions in countries like the U.K., Italy, Germany, France, etc. 

The Asia Pacific is accounted for having the fastest growth rate the past decade and is also estimated to hit the highest CAGR in the coming years. The increasing elderly population is a common factor in the market's growth.

The Middle East and Africa are deemed to have growth opportunities in the review period.

KEY MARKET PLAYERS

Noteworthy companies in the Global C-Arms Market profiled in the report are GE Healthcare Inc., Varian Medical Systems Inc., Philips Healthcare, Siemens AG, Toshiba Corp, Hologic Corp, Omega Medical Imaging Inc., BMI Biomedical International, Hitachi Ltd, DMS Health Technologies, ATON GmbH, Medonica Co Ltd, Gemss Co Ltd, and Shimadzu Corp.

RECENT MARKET HAPPENINGS

• In October 2022, the main TIM-3 lung cancer trial by GSK will be launched after the phase 2 hurdle is overcome. After doing well in the study's mid-phase, GSK's anti-TIM-3 antibody is now entering a pivotal trial, solidifying Big Pharma's position as the front-runner in a field that includes Novartis.
• The checkpoint receptor TIM-3 is the most recent target to capture the attention of the immuno-oncology community. Given the failure of Roche's candidate and the waning interest in TIGIT, another checkpoint receptor, TIM-3, could potentially take center stage. However, businesses still need to present data to demonstrate that they can avoid the tragic outcomes of earlier hot immuno-oncology targets.
• In October 2022, late-breaking Phase 3 data on Dupixent® (dupilumab) presented at UEG Week 2022 demonstrated a significant histological remission of eosinophilic esophagitis (EoE) in children aged 1 to 11. In a Phase 3 trial, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi evaluated the practical use of Dupixent® (dupilumab) in children aged 1 to 11 with active eosinophilic esophagitis. Today, the study's late-breaking favorable results were presented (EoE). The information will be disseminated at the United European Gastroenterology Week in 2022 and submitted to regulatory agencies worldwide, beginning with the U.S. Food and Drug Administration (FDA) the following year. As a result, the FDA authorized Dupixent 300 mg once a week in May 2022 for the treatment of EoE in patients 12 years of age and older who weighed at least 40 kg.
• In January 2022, the company stated that physicians will now have access to cutting-edge new 3D image guiding capabilities with Philips Healthcare's Image-Guided Therapy Mobile C-arm System Zenition. The company claimed that the technology would improve endovascular patient outcomes by delivering increased clinical accuracy and efficiency. In addition, to plan and direct surgery in real-time, the business has partnered with Cydar, a U.K.-based cloud-based process maps software provider.
• Patient-specific real-time procedure planning and guiding, optimization of equipment utilization, and usability have become increasingly crucial as patient numbers increase and operations become more complicated and time-consuming. Philips Image-Guided Therapy Mobile C-arm System Zenition combines advances in image capture and processing, usability, and mobility to overcome these difficulties.
• In January 2020, Philips introduced its two new devices to the X-Ray system. Those are named Zenition mobile C-arm platforms and enhancing operating room workflow. Zenition mobile c-arm has a tableside user interface where the technicians can operate efficiently in the sterile field.
• In January 2018, Hologic introduced a new Fluoroscan Insight FD Mini C-Arm where the surgeons, like orthopedists and podiatrists, use these devices. First, the surgeons can adjust the device according to the patient's needs, like high resolution or low dosages. Then, the device controls the system and views the results.
• In September 2011, OrthoScan, Inc. was acquired by ATON GmbH. Orthoscan, Inc. is a prime manufacturer of orthopedic imaging products, including small C-arms. With this acquisition, both companies operate under a joint holding formation that will generate considerable interaction in the upcoming years.

MARKET SEGMENTATION

This research report on the Global C-Arms Market has been segmented and sub-segmented based on the device type, application, and region.

By Device Type

• Fixed C-Arms
• Mobile C-Arms
  • Mini C-Arms
  • Full-Size C-Arms

By Application

• Cardiovascular
• Neurology
• Urology
• Orthopedic
• Pain Management and Trauma
• Gastrointestinal
• General Surgery

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa